The synthesis of well-defined polypeptides show complex macromolecular architecture requires the use of monomers that can be grouped by orthogonally grouped, containing primary amines that will be used as initiary for polymerization of the ring opening (ROP) anhydride n-carboxy. Synthesis and characterization of novel nε-9-fluorylmethoxycarbony-ls-carboxy anhydride (Na-FMOC-Lysine NCA), as well as linear poly novel (Nε-FMOC-L-Lys) n homopipeptide and poly (L-lysine) 78- Block- [Poly (L-Lysine) 10-graft-poly (L-Histidine) 15] Copolypeptide block-graft, served.
The copolypeptide graft synthesis was carried out through the NA-BOC-L-Lysine NCA ROP when using n-hexylamine as an initiator, followed by the polymerization of NCA Nε-FMOC-L-lysine. The latest blocks are selectively explored in basic conditions, and the resulting ε-amine is used as an initiation species for ROP NIM-Trity-L-Histidine NCA. Finally, the Board of Commissioners and Trt groups were sentenced by TFA. High vacuum techniques are applied to achieve the conditions needed for well-defined polypeptide synthesis. Molecular characterization shows that polypeptides show molecular homogeneity and high composition.
Finally, dynamic light scattering, ζ-potential, and a circular crocated measurement is used to investigate the ability of polypeptides to gather itself in different conditions. This monomer paves the way for polypeptide synthesis with complex macromolecular architecture that can define aggregation behavior, and, therefore, can cause the synthesis of responsive nanocarrier “smart” stimulation for controlled drug delivery applications.
Antimicrobial multifunctional polypeptide-selenium nanoparticles combating drug resistance bacteria
Antibiotic-resistant bacteria are severe threats to human health. The global global surveillance system of the Health Health Health has revealed antibiotic resistance between half a million patients in 22 countries, with Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae became the most resistant species. Antimicrobial nanoparticles emerged as an alternative that promised antibiotics in the fight against antimicrobial resistance. In this work, selenium nanoparticles are coated with antimicrobial polypeptides, ε-poly-licin, (SE np-ε-pl) synthesized and antibacterial activity and cytotoxicity investigated. SE NP-ε-PL which shows significantly larger antibacterial activity of all eight species of bacteria tested, including gram-positive, gram-negative strains, and drug resistance, than their individual components, SE NP and ε-pl.
Nanoparticles do not show toxicity to human dermal fibroblasts at the minimum inhibitory concentration, showing therapeutic windows. Furthermore, unlike conventional kanamycin antibiotics, SE NP-ε-PL does not easily induce resistance to E. coli or S. aureus. In particular, S. aureus began developing resistance to Kanamycin from the generation of ~ 44, while needed ~ 132 generations for resistance to develop into SE np-ε-pl. Surprisingly, E. coli cannot develop resistance to nanoparticles above ~ 300 generations. These results indicate that the multifunctional approach to combining SE NP with ε-PL to form SE NP-ε-PL is a new strategy that is very efficacious with the antibacterial activity of the width spectrum, low cytotoxicity, and significant delay in the development of resistance.
Open polypeptides open surface are successfully used as targets to develop a one-step prototype immunochromatography strip for specific and sensitive direct detection of staphylococcus aureus which causes neonatal sepsis
Neonatal sepsis is a life-threatening condition and Staphylococcus aureus is one of the main causes. However, until now, there are no fast and sensitive diagnostic tools have been developed for direct detection. Bioinformatics analysis identifies 112 amino acid polypeptides exposed to the surface of the cell protein nwmn_1649 cell walls, surface protein involved in cell aggregation and biofilm formation, as specific species and moiety which is highly preserved.

Polypeptides are cloned, purified, and used to immunize mice to increase certain immunoglobulin. Purified antibodies are conjugated to gold nano particles and are used to assemble immunochromatographic strips (ICS). The prototype IC developed is detected as low as 5 μg of pure polypeptides and 102 CFU / ML S. aureus in 15 minutes. The strip shows superior ability to directly detect S. aureus in the blood specimens of neonatal sepsis without previous sample processing. In addition, it does not show cross reactions in specimens infected with two other main causes of neonatal sepsis; Koagulase-negative Staphylococci and Klebsiella pneumoniae. The selected NWMN_1649 polypeptide shown shows success as a promising biomolecule where IC prototypes have been developed. This ICS provides fast, direct, sensitive and specific options for S. aureus detection which causes neonatal sepsis. Such tools are needed especially in limited countries of resources.
Stabilization of oil emulsion in soybean water using multilayers polypeptides: cationic polylysine and anionic acid polyglutamate
Oil-in-water emulsions are used as a shipping system for non-polar functional materials in various industries, including food, cosmetics, personal care products, agrochemicals and pharmaceuticals. However, emulsions tend to be damaged in conditions found in many commercial products. In this study, the functional performance of lipid droplets in emulsions is adjusted to electrostatic deposition of layers after the sequential layers of charged polypeptides contrary to their surface. Cationic Poly-L-lysine (PLL) and anionic poly-glutamic acid (PGA) are used as a pair of polypeptides imposed on the opposite (pH 4.0).
First, the primary emulsion (10% W / W soybean oil emulsion) is formed consisting of small lipid droplets (D32 = 500 μm) coated by natural surfactants (0.05% w / w Quilleta Saponin). Second, Cationic PLL is saved to the surface of anionic saponin-plated droplets. Third, Anionic PGA was saved to the surface of the cationic PLL-Saponin-plated droplets. We then assess the ability of coatings to protect lipid droplets from aggregation when pH (2.0-9.0), ionic power (0-350 mm), or temperature (30-90 ° C) changed. Primary, secondary and tertiary emulsion properties are monitored by measuring the average particle diameter (D32), electrical characteristics (ζ-potential), and micro from lipid droplets.
TKD Peptide (Hsp70 Peptide) |
abx076809-1mg |
Abbexa |
1 mg |
EUR 594 |
|
Rat Peptide YY (PYY) Peptide |
20-abx068453 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Connecting Peptide (C-Peptide) Peptide |
abx670072-05mg |
Abbexa |
0.5 mg |
EUR 678 |
|
Human Peptide YY (PYY) Peptide |
20-abx068451 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Peptide YY (PYY) Peptide |
20-abx068452 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
TKD Peptide (Hsp70 Peptide) (FITC) |
abx076810-1mg |
Abbexa |
1 mg |
EUR 678 |
|
Rat Connecting Peptide (C-Peptide) Peptide (OVA) |
20-abx651058 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1378.80
-
EUR 594.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Peptide YY (PYY) Peptide (OVA) |
20-abx651198 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Peptide YY (PYY) Peptide (OVA) |
20-abx651200 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Peptide YY (PYY) Peptide (OVA) |
20-abx651201 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Peptide YY (PYY) Peptide (OVA) |
20-abx651199 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Peptide YY (PYY) Peptide (OVA) |
20-abx651848 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Galanin Like Peptide (GALP) Peptide |
20-abx650475 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2364.00
-
EUR 927.60
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Peptide 810 |
H-2586.0001 |
Bachem |
1.0mg |
EUR 529.2 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
Peptide 810 |
H-2586.0005 |
Bachem |
5.0mg |
EUR 2010 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
TATA Box Binding Protein (TBP) Blocking Peptide |
20-abx161483 |
Abbexa |
|
|
|
Formyl Peptide Receptor-like 2 Peptide |
43-293P |
ProSci |
0.1 mg |
EUR 405.6 |
Dog Brain Natriuretic Peptide (BNP) Peptide |
20-abx065598 |
Abbexa |
-
EUR 1062.00
-
EUR 393.60
-
EUR 3400.80
-
EUR 1262.40
-
EUR 727.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Brain Natriuretic Peptide (BNP) Peptide |
20-abx065601 |
Abbexa |
-
EUR 994.80
-
EUR 376.80
-
EUR 3199.20
-
EUR 1195.20
-
EUR 693.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Brain Natriuretic Peptide (BNP) Peptide |
20-abx652109 |
Abbexa |
-
EUR 910.80
-
EUR 360.00
-
EUR 2865.60
-
EUR 1095.60
-
EUR 644.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Canine C Peptide(C Peptide) ELISA Kit |
ECA0028 |
FN Test |
96T |
EUR 681.12 |
|
Description: Method of detection: Coated with Antigen, Competitive ELISA;Reacts with: Canine;Sensitivity: 0.469 ng/ml |
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065483 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065484 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065486 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cow Atrial Natriuretic Peptide (ANP) Peptide |
20-abx166288 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2766.00
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide |
20-abx065599 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2766.00
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Brain Natriuretic Peptide (BNP) Peptide |
20-abx065600 |
Abbexa |
-
EUR 895.20
-
EUR 360.00
-
EUR 2798.40
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Brain Natriuretic Peptide (BNP) Peptide |
20-abx065602 |
Abbexa |
-
EUR 895.20
-
EUR 360.00
-
EUR 2798.40
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain natriuretic peptide (BNP) Peptide |
abx670010-01mg |
Abbexa |
0.1 mg |
EUR 360 |
|
Human Osteogenic Growth Peptide (OGP) Peptide |
20-abx652290 |
Abbexa |
-
EUR 661.20
-
EUR 292.80
-
EUR 1914.00
-
EUR 777.60
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065482 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Atrial Natriuretic Peptide (ANP) Peptide |
20-abx652084 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069656 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Vasoactive Intestinal Peptide (VIP) Peptide (OVA) |
20-abx651057 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cow Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx166274 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat C- Peptide, connecting peptide ELISA Kit |
CELI-66099r |
Lifescience Market |
96 Tests |
EUR 1063.2 |
Glucagon-Like Peptide 1 (GLP1) Peptide (OVA) |
20-abx651107 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1378.80
-
EUR 594.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069654 |
Abbexa |
-
EUR 794.40
-
EUR 326.40
-
EUR 2448.00
-
EUR 944.40
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069655 |
Abbexa |
-
EUR 828.00
-
EUR 343.20
-
EUR 2548.80
-
EUR 978.00
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx652275 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human C- Peptide, connecting peptide ELISA Kit |
CELI-66099h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Mouse C- Peptide, connecting peptide ELISA Kit |
CELI-66099m |
Lifescience Market |
96 Tests |
EUR 1038 |
Rat C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066176 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Gastrin Releasing Peptide (GRP) Peptide (OVA) |
20-abx651230 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glucagon-Like Peptide 2 (GLP2) Peptide |
abx670345-1mg |
Abbexa |
1 mg |
EUR 427.2 |
|
PEPT2 Peptide |
42-289P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (CT) PEPT2 Peptide |
Bovine C- Peptide, connecting peptide ELISA Kit |
CELI-66099b |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Canine C- Peptide, connecting peptide ELISA Kit |
CELI-66099d |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Rabbit C- Peptide, connecting peptide ELISA Kit |
CELI-66099Rb |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Cow Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651048 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651049 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651051 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
HA Peptide |
20-abx266124 |
Abbexa |
-
EUR 493.20
-
EUR 794.40
-
EUR 376.80
|
|
|
HP Peptide |
42-911P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) HP beta chain peptide |
HP Peptide |
42-912P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) HP alpha chain peptide |
C3 Peptide |
43-098P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: C3 Peptide |
C3 Peptide |
43-099P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: C3 Peptide |
C9 Peptide |
43-483P |
ProSci |
0.1 mg |
EUR 405.6 |
KL Peptide |
42-061P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) Klotho / KL Peptide |
Peptide e |
H-3236.0500 |
Bachem |
0.5mg |
EUR 327.6 |
Description: Sum Formula: C83H155N39O21S; CAS# [120253-69-2] |
Peptide e |
H-3236.1000 |
Bachem |
1.0mg |
EUR 559.2 |
Description: Sum Formula: C83H155N39O21S; CAS# [120253-69-2] |
Peptide 46 |
H-4054.0500 |
Bachem |
0.5mg |
EUR 618 |
Description: Sum Formula: C100H174N40O31; CAS# [192122-40-0] |
Peptide 46 |
H-4054.1000 |
Bachem |
1.0mg |
EUR 1082.4 |
Description: Sum Formula: C100H174N40O31; CAS# [192122-40-0] |
Peptide 6A |
H-6905.0005 |
Bachem |
5.0mg |
EUR 356.4 |
Description: Sum Formula: C23H43N9O6; CAS# [73549-32-3] |
Peptide 6A |
H-6905.0025 |
Bachem |
25.0mg |
EUR 1311.6 |
Description: Sum Formula: C23H43N9O6; CAS# [73549-32-3] |
Peptide 74 |
H-8545.0500 |
Bachem |
0.5mg |
EUR 254.4 |
Description: Sum Formula: C62H107N23O20S2; CAS# [132116-39-3] |
Peptide 74 |
H-8545.1000 |
Bachem |
1.0mg |
EUR 400.8 |
Description: Sum Formula: C62H107N23O20S2; CAS# [132116-39-3] |
Rat Cathelicidin Antimicrobial Peptide (CAMP) Peptide |
20-abx065801 |
Abbexa |
-
EUR 895.20
-
EUR 343.20
-
EUR 2781.60
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Chicken C- Peptide, connecting peptide ELISA Kit |
CELI-66099c |
Lifescience Market |
96 Tests |
EUR 1113.6 |
General C- Peptide, connecting peptide ELISA Kit |
CELI-66099Ge |
Lifescience Market |
96 Tests |
EUR 1063.2 |
Porcine C- Peptide, connecting peptide ELISA Kit |
CELI-66099p |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Human C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066173 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066174 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066178 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Antigen Peptide Transporter 2 (TAP2) Peptide |
20-abx650297 |
Abbexa |
-
EUR 727.20
-
EUR 309.60
-
EUR 2197.20
-
EUR 861.60
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (BSA) |
20-abx651076 |
Abbexa |
-
EUR 393.60
-
EUR 243.60
-
EUR 1011.60
-
EUR 477.60
-
EUR 326.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651077 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651078 |
Abbexa |
-
EUR 309.60
-
EUR 226.80
-
EUR 678.00
-
EUR 343.20
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651079 |
Abbexa |
-
EUR 326.40
-
EUR 226.80
-
EUR 727.20
-
EUR 360.00
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651080 |
Abbexa |
-
EUR 309.60
-
EUR 226.80
-
EUR 678.00
-
EUR 343.20
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Gastrin Releasing Peptide (GRP) Peptide (BSA) |
20-abx651228 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1262.40
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Gastrin Releasing Peptide (GRP) Peptide (OVA) |
20-abx651229 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide |
20-abx652283 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide |
abx670346-1mg |
Abbexa |
1 mg |
EUR 627.6 |
|
Rat Natriuretic Peptide Receptor 3 (NPR3) Peptide |
20-abx168540 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2749.20
-
EUR 1045.20
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Calcitonin Gene Related Peptide (CGRP) Peptide |
20-abx065659 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Horse Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651788 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Glucagon Like Peptide 2 (GLP2) Peptide (OVA) |
20-abx651864 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
ADM Peptide |
20-abx265198 |
Abbexa |
-
EUR 594.00
-
EUR 978.00
-
EUR 427.20
|
|
|
PHI Peptide |
20-abx265548 |
Abbexa |
-
EUR 360.00
-
EUR 477.60
-
EUR 678.00
|
|
|
RGD Peptide |
20-abx265712 |
Abbexa |
-
EUR 393.60
-
EUR 594.00
-
EUR 326.40
|
|
|
APP Peptide |
20-abx265758 |
Abbexa |
-
EUR 393.60
-
EUR 594.00
-
EUR 326.40
|
|
|
NAP Peptide |
20-abx265958 |
Abbexa |
-
EUR 460.80
-
EUR 710.40
-
EUR 360.00
|
|
|
TRH Peptide |
20-abx266017 |
Abbexa |
-
EUR 477.60
-
EUR 760.80
-
EUR 376.80
|
|
|
NPV Peptide |
20-abx266133 |
Abbexa |
-
EUR 493.20
-
EUR 794.40
-
EUR 376.80
|
|
|
SP1 Peptide |
20-abx266405 |
Abbexa |
-
EUR 627.60
-
EUR 1045.20
-
EUR 460.80
|
|
|
SP2 Peptide |
20-abx266460 |
Abbexa |
-
EUR 661.20
-
EUR 1111.20
-
EUR 477.60
|
|
|
NGR peptide |
B1434-10 |
ApexBio |
10 mg |
EUR 201.6 |
Description: NGR peptide |
NGR peptide |
B1434-50 |
ApexBio |
50 mg |
EUR 517.2 |
Description: NGR peptide |
DR3 Peptide |
1120P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) DR3 peptide |
NIK Peptide |
1129P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) NIK peptide |
DR3 Peptide |
1158P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (ED) DR3 peptide |
DR3 Peptide |
1166P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) DR3 peptide |
DR4 Peptide |
1167P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) DR4 peptide |
DR4 Peptide |
1139P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) DR4 peptide |
AIF Peptide |
2301P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) AIF peptide |
TP1 Peptide |
2345P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) TP1 peptide |
PID Peptide |
2443P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: PID peptide |
APP Peptide |
2136P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) APP peptide |
DR6 Peptide |
2157P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: DR6 peptide |
ARC Peptide |
2185P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) ARC peptide |
AIF Peptide |
2239P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) AIF peptide |
Ski Peptide |
2259P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) Ski peptide |
AIF Peptide |
2267P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) AIF peptide |
ASC Peptide |
2287P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: ASC peptide |
The electrical characteristics of droplets can be modulated by controlling the number and type of layer used. Primary emulsions have the best resistance to various environmental conditions, while secondary emulsions have the worst, suggest electrostatic deposits may only be used to get certain functions. Interestingly, PLL regardless of the surface of the secondary emulsion at high salt concentrations due to electrostatic screening, which increases their salt stability. This phenomenon may be useful for several food applications, eg, have cationic droplets during food storage, but are anionic in the human body.